Figure 2.

B2 CAR T-cells are more potent in eradicating tumors in vivo compared to B1 CAR. (A) In the in vivo tumor model, 8 x 10⁶ RPMI-8226 cells were intradermally injected on the abdomen of NSG mice (all groups n = 8, except untreated, n = 5) and allowed to engraft for 17 days before the intravenous injection of T-cells. Five million CAR T-positive -cells was infused per mouse, normalized based on CAR expression, or equivalent amount of non-transduced T cells (UTD), or left untreated. Mice were monitored for (B) tumor growth and (C) survival. Statistical significance was determined by paired Student t-test for the indicated groups, *p<0.05, **p<0.01, ***p<0.001.